Our study is the first, to our knowledge, to evaluate both genetic and pharmacologic modulation of NUAK2 in GBM, and it provides preclinical rationale for NUAK2 as a candidate therapeutic target. This evidence concerns the gene NUAK2 and glioblastoma.